TO THE PHARMACIST
... LYRICA at doses of 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset seizures in adults. Both the efficacy and adverse event profiles of LYRICA have been shown to be dose-related. Administer the total daily dose in two or three divided doses. In ...
... LYRICA at doses of 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset seizures in adults. Both the efficacy and adverse event profiles of LYRICA have been shown to be dose-related. Administer the total daily dose in two or three divided doses. In ...
OsmoPrep - Salix Pharmaceuticals
... In controlled colon preparation trials of OsmoPrep, 228 (24%) of 931 patients were 65 years of age or older. In addition, 49 (5%) of the 931 patients were 75 years of age or older. Of the 228 geriatric patients in the trials, 134 patients (59%) received at least 48 grams of OsmoPrep. Of the 49 patie ...
... In controlled colon preparation trials of OsmoPrep, 228 (24%) of 931 patients were 65 years of age or older. In addition, 49 (5%) of the 931 patients were 75 years of age or older. Of the 228 geriatric patients in the trials, 134 patients (59%) received at least 48 grams of OsmoPrep. Of the 49 patie ...
www.healthoracle.org 1 Methyl Sulfonyl Methane (MSM) MSM
... Some researchers have suggested that the resulting MSM could be responsible for the benefits attributed to DMSO. MSM might be preferable as a treatment, because it does not cause some of the unpleasant side effects associated with DMSO treatment, such as body odor and bad breath. In addition, as a n ...
... Some researchers have suggested that the resulting MSM could be responsible for the benefits attributed to DMSO. MSM might be preferable as a treatment, because it does not cause some of the unpleasant side effects associated with DMSO treatment, such as body odor and bad breath. In addition, as a n ...
PASS assisted search and evaluation of some azetidin-2
... taken by the animal to enter in closed arm was noted as transfer latency (TL), one hour before and 24 hours after administering the test drugs. Test compounds 5j, 5b and 5n (5.0 mg/kg) and reference standard piracetam (3mg/kg) were administered orally in the form of suspension in 0.5% CMC solution. ...
... taken by the animal to enter in closed arm was noted as transfer latency (TL), one hour before and 24 hours after administering the test drugs. Test compounds 5j, 5b and 5n (5.0 mg/kg) and reference standard piracetam (3mg/kg) were administered orally in the form of suspension in 0.5% CMC solution. ...
Drug information Question
... The primary outcome of the post hoc analysis was mortality.3 In terms of this outcome, women were associated with an increased risk of death with digoxin use (33.1% in the digoxin group vs. 28.9% in the placebo group; absolute difference, 4.2%; 95% confidence interval, -0.5 to 8.8; P=0.034), but the ...
... The primary outcome of the post hoc analysis was mortality.3 In terms of this outcome, women were associated with an increased risk of death with digoxin use (33.1% in the digoxin group vs. 28.9% in the placebo group; absolute difference, 4.2%; 95% confidence interval, -0.5 to 8.8; P=0.034), but the ...
Product Information: Taladafil
... improvement compared to placebo. Additionally, partners of patients on tadalafil had statistically significant greater satisfaction with sexual activity compared to partners of patients on placebo. Tadalafil at doses of 2 to 100 mg has been evaluated in 16 clinical studies involving 3250 patients. T ...
... improvement compared to placebo. Additionally, partners of patients on tadalafil had statistically significant greater satisfaction with sexual activity compared to partners of patients on placebo. Tadalafil at doses of 2 to 100 mg has been evaluated in 16 clinical studies involving 3250 patients. T ...
Paclitaxel-coated Angioplasty Catheters for Local Drug Delivery
... field of drug-coated balloons. In addition, he is the principal investigator and initiator of several clinical trials in peripheral vascular intervention, and in 2003 he won the German Röntgenpreis based on his experimental work on the prevention of restenosis with coated stents. Professor Tepe is a ...
... field of drug-coated balloons. In addition, he is the principal investigator and initiator of several clinical trials in peripheral vascular intervention, and in 2003 he won the German Röntgenpreis based on his experimental work on the prevention of restenosis with coated stents. Professor Tepe is a ...
COSOPT Combination Ophthalmic Solution
... Information provided in this press release contains so-called “Forward-looking Statements”. The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance a ...
... Information provided in this press release contains so-called “Forward-looking Statements”. The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance a ...
the absorption, distribution, metabolism and excretion of rofecoxib, a
... potent and highly selective inhibitor of cyclooxygenase-2 (COX-2). In rats, the nonexponential decay during the terminal phase (4- to 10-h time interval) of rofecoxib plasma concentration versus time curves after i.v. or oral administration of [14C]rofecoxib precluded accurate determinations of half ...
... potent and highly selective inhibitor of cyclooxygenase-2 (COX-2). In rats, the nonexponential decay during the terminal phase (4- to 10-h time interval) of rofecoxib plasma concentration versus time curves after i.v. or oral administration of [14C]rofecoxib precluded accurate determinations of half ...
Ciproxin Tablets 250mg - electronic Medicines Compendium (eMC
... Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents. Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised d ...
... Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents. Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised d ...
HƯỚNG DẪN VỀ DƯỢC PHẨM INCIVEK
... ----------------------------INDICATIONS AND USAGE--------------------------INCIVEK is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated, in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated live ...
... ----------------------------INDICATIONS AND USAGE--------------------------INCIVEK is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated, in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated live ...
Adjunct to anesthesia One of a number of drugs or techniques used
... • Pure agonists stimulate all receptors – morphine, fentanyl and oxymorphone • Mixed agonists/antagonists block one type of receptor and stimulate another • Pure antagonists such as naloxone will reverse the effects of pure and mixed agonists with very little clinical effect on their own Also classi ...
... • Pure agonists stimulate all receptors – morphine, fentanyl and oxymorphone • Mixed agonists/antagonists block one type of receptor and stimulate another • Pure antagonists such as naloxone will reverse the effects of pure and mixed agonists with very little clinical effect on their own Also classi ...
sleor 1 DecembeO, 2006 L.
... Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy. ...
... Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy. ...
Stereoselective inhibition of the hERG1 potassium channel
... Their results suggested that CYP2D6, CYP2C9, and CYP3A4 greatly contribute to the hepatic metabolism of this chiral antidepressant drug. In a contemporaneous study, stereoselective biotransformation of racemic fluoxetine was assessed in CYP2D6 sparteine slow and extensive metabolizers (Fjordside et ...
... Their results suggested that CYP2D6, CYP2C9, and CYP3A4 greatly contribute to the hepatic metabolism of this chiral antidepressant drug. In a contemporaneous study, stereoselective biotransformation of racemic fluoxetine was assessed in CYP2D6 sparteine slow and extensive metabolizers (Fjordside et ...
acris combi
... The mean steady state volume of distribution is 6.3 L/kg in humans. Human plasma protein binding of risedronate is about 24%. Preclinical studies in rats and dogs dosed intravenously with single doses of [14C] risedronate indicate that 40-45% of the dose was distributed in the bone after 72 hours. A ...
... The mean steady state volume of distribution is 6.3 L/kg in humans. Human plasma protein binding of risedronate is about 24%. Preclinical studies in rats and dogs dosed intravenously with single doses of [14C] risedronate indicate that 40-45% of the dose was distributed in the bone after 72 hours. A ...
Neurogenic temporomandibular joint dislocation treated with
... trauma in 2003 as the result of a traffic accident. After the accident, he presented multiple foci of brain contusions, with subarachnoid bleeding in the third and lateral ventricles, the right thalamus, and the right occipital cortex. These injuries led to the presence of chronic subdural haematoma ...
... trauma in 2003 as the result of a traffic accident. After the accident, he presented multiple foci of brain contusions, with subarachnoid bleeding in the third and lateral ventricles, the right thalamus, and the right occipital cortex. These injuries led to the presence of chronic subdural haematoma ...
Volume 6 Issue 11 - eCysticFibrosis Review
... An important challenge for clinicians is how to optimize the use of CFTR modulators in their patients. Considerations include selecting patients on the basis of genotype, ability to adhere to therapy, and severity of disease. Despite the promise of benefit with ivacaftor, adherence may not be much b ...
... An important challenge for clinicians is how to optimize the use of CFTR modulators in their patients. Considerations include selecting patients on the basis of genotype, ability to adhere to therapy, and severity of disease. Despite the promise of benefit with ivacaftor, adherence may not be much b ...
Product Monograph
... M-ESLON Capsules (Morphine Sulfate Extended Release Capsules) produce peak morphine levels at steady state in approximately 3 to 4 hours following administration. In human pharmacokinetic studies, they have been shown to have an extended release action, when compared to oral morphine sulfate syrup, ...
... M-ESLON Capsules (Morphine Sulfate Extended Release Capsules) produce peak morphine levels at steady state in approximately 3 to 4 hours following administration. In human pharmacokinetic studies, they have been shown to have an extended release action, when compared to oral morphine sulfate syrup, ...
PAXIL CR™ PRODUCT MONOGRAPH
... platelet aggregation may result from platelet serotonin depletion and contribute to such occurrences. Skin and mucous membrane bleedings (including upper gastrointestinal bleeding) have been reported following treatment with paroxetine IR. Paroxetine CR™ should therefore be used with caution in pati ...
... platelet aggregation may result from platelet serotonin depletion and contribute to such occurrences. Skin and mucous membrane bleedings (including upper gastrointestinal bleeding) have been reported following treatment with paroxetine IR. Paroxetine CR™ should therefore be used with caution in pati ...
Factrel® Injection
... Injection and FTAI was conducted 24 or 17 hours later, respectively. For control cows FTAI was performed 72 hours after the LUTALYSE Injection dose was administered. All treatment groups had significantly greater pregnancy rates to FTAI than cows administered LUTALYSE Injection alone, and were 17.1, ...
... Injection and FTAI was conducted 24 or 17 hours later, respectively. For control cows FTAI was performed 72 hours after the LUTALYSE Injection dose was administered. All treatment groups had significantly greater pregnancy rates to FTAI than cows administered LUTALYSE Injection alone, and were 17.1, ...
When Can Successful Migraine Prophylaxis Be Discontinued?
... patients. This is a matter of intense debate. Unfortunately, most trials of prophylactic agents do not occur over a long enough period to evaluate their effect on disease progression and despite our long clinical experience with propranolol, a systematic review of its use for migraine prophylaxis co ...
... patients. This is a matter of intense debate. Unfortunately, most trials of prophylactic agents do not occur over a long enough period to evaluate their effect on disease progression and despite our long clinical experience with propranolol, a systematic review of its use for migraine prophylaxis co ...
PDF
... studies are still needed before the clinical trials. Although providing the best available data regarding human proarrhythmic risk for drug dose selection in the first-in-human studies, the animal models are still an imperfect predictor of the torsadogenic risk in humans. Nonrodent (dog, monkey, swi ...
... studies are still needed before the clinical trials. Although providing the best available data regarding human proarrhythmic risk for drug dose selection in the first-in-human studies, the animal models are still an imperfect predictor of the torsadogenic risk in humans. Nonrodent (dog, monkey, swi ...
Ro 11-2465 (cyan-imipramine), citalopram and their N
... when used in higher doses (>0.1 mg/kg). Only Ro 12-5419 and Ro 11-2465 were able to potentiate the pressor response to NA. Ro 12-5419 also potentiated thyrotropin releasing hormone (TRH) hyperthermia and antagonized reserpine hypothermia in mice; Ro ! 1-2465 potentiated the TRH hyperthermia only. CI ...
... when used in higher doses (>0.1 mg/kg). Only Ro 12-5419 and Ro 11-2465 were able to potentiate the pressor response to NA. Ro 12-5419 also potentiated thyrotropin releasing hormone (TRH) hyperthermia and antagonized reserpine hypothermia in mice; Ro ! 1-2465 potentiated the TRH hyperthermia only. CI ...
... The development of the inhalation profile simulator (or Electronic Lung™) [7] has enabled us to rigorously test powder inhalers in a realistic model of inhalation behaviour by using inhalation profiles collected from our patients. Patient ability to inhale a dose of drug as respirable particles is a ...
- Journal of Pharmacognosy and Phytochemistry
... Paracetamol 100 mg/kg per orally was used for comparison. The reduction in pyrexia after Clerodendrum serratum administration indicated the antipyretic activity of this plant. The response at higher doses was almost comparable to that of paracetamol (Narayanan et al, 1999) [14]. 6.7 Analgesic activi ...
... Paracetamol 100 mg/kg per orally was used for comparison. The reduction in pyrexia after Clerodendrum serratum administration indicated the antipyretic activity of this plant. The response at higher doses was almost comparable to that of paracetamol (Narayanan et al, 1999) [14]. 6.7 Analgesic activi ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.